《大行報告》野村首予藥明生物(02269.HK)「買入」評級 目標價213.1元
野村發表研究報告,首次覆蓋藥明生物(02269.HK),予其股份「買入」評級,目標價213.1元,認為集團可繼續擴展其市場佔有率,不過來自國際同業的競爭為主要憂慮。
該行表示,藥明生物於去年底有43個處第二及三期的綜合項目,或可於未來三至六年申請新藥上市,處後期項目的增長料有助推動集團盈利提升,估計至2023年其將有9個商業項目。而商業項目於2030年底預期可貢獻543億元人民幣收入,佔集團收入57%。
另外,野村預計藥明生物將收到20至30個與新型冠狀病毒治療相關的項目,可部分抵銷臨床前項目的取消,和延遲確認里程碑付款而造成的約1億美元損失。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.